AstraZeneca (AZ) has announced that its immunotherapy Imfinzi (durvalumab) has been approved by the European Commission (EC) ...

Imfinzi has been approved in the European Union as monotherapy for the treatment of adults with limited-stage small cell ...

AstraZeneca's eneboparatide met its Phase 3 trial goal for chronic hypoparathyroidism, while the EU approved Imfinzi for ...

The safety profile for Imfinzi was generally manageable and consistent with the known profile of this medicine.

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) as monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not ...

The European Commission approves AstraZeneca's Imfinzi for treating patients with limited-stage small-cell lung cancer based ...

Dave Fredrickson, Executive Vice President of AstraZeneca’s Oncology Haematology Business Unit, emphasized Imfinzi’s potential to transform LS-SCLC treatment, noting that it is now the only ...

IMFINZITM (durvalumab) has received approval in the European Union as a monotherapy for treating adults with limited-stage ...

Approval based on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo ...

AstraZeneca PLC (LSE/STO/Nasdaq: LON:AZN), a pharmaceutical giant with a market capitalization of $237 billion and impressive 82% gross profit margin, announced today that its immunotherapy drug, ...

Despite resubmitting after an initial complete response letter (CRL) due to manufacturing issues, the combination therapy ...